Please Wait...

Alzheimer's Association International Conference (AAIC)

July 22, 2018 - 1:00am (EDT) to July 26, 2018 - 1:00am (EDT)

 

July 20-21 Preconference

Alzheimer's Association International Conference (AAIC)   AAIC, Chicago, Illinois

Join us for AAIC in Chicago where international investigators, clinicians and care providers will gather to share the latest study results, theories and discoveries to help bring the world closer to breakthroughs in dementia science.

Bioclinica Alzheimer's Disease experts will present findings in six different scientific poster presentations, some of which will be presented in multiple sessions over the course of the AAIC preconference and conference.

We invite you to join us in the following poster sessions:

  • Prediction of Conversion to Dementia Based on Demographic, Clinical and Imaging Baseline Characteristics. Nicolas Pannetier, PhD, Luc Bracoud, Joel Schaerer, Katarzyna Adamczuk, PhD, Mehul Sampat, Joyce Suhy, PhD and Dave Scott, PhD, Bioclinica, in collaboration with the Alzheimer's Disease Neuroimaging Initiative.
    Session Details: Alzheimer's Imaging Consortium (AIC) Preconference, IC-P-104: July 21, 12:30 – 1:45 PM in Hall -F1 and also P3-427, July 24, 9:30 AM– 4:15 PM
    Summary: MCI represents a transitional stage from normal aging to AD. However, only a subset of MCI patients converts to AD. Predicting conversion is of critical importance to develop meaningful eligibility criteria for clinical trials that aim at delaying AD onset. Various biomarkers are potential candidates but their predictive value is still unclear. This study investigated which biomarker(s) lead to the highest predictivity.
  • Baseline Florbetapir Amyloid PET Standard Uptake Value Ratio (SUVR) Predicts Clinical Stage in Pre-clinical Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). Shobha Dhadda,1 Chad J. Swanson,1David Scott, PhD,2 Yong Zhang,1 Jim Zhao,1 Jinping Wang,1 Johan Luthman,1 Lynn Kramer1,1 Eisai Inc.2 Bioclinica
    Session Details: Developing Topic: P4-291: July 25, 9:30 AM – 4:15 PM in Hall F-1
    Summary: Previous analyses suggest Aβ-related amyloid load is not correlated with cognitive change in Alzheimer's Disease (Daniela et al 2014); primarily based on studies in patients with clinical dementia. This finding could be related to the initiation of a cascade of cognitive impairment caused by amyloid saturation, thus no longer responsive to change, i.e. much like reaching a plateau of a dose-response curve. We therefore hypothesized that there might be a correlation prior to amyloid plaque saturation. In addition, we hypothesized that correlation would not be seen at lower plaque loads, as cognition is not sufficiently impaired at this early stage of disease. Here is shown an optimal range of baseline amyloid PET Standard Uptake Value Ratios (SUVR) can predict cognitive decline over 24 months in prodromal AD (pAD) subjects.
  • Comparative Study of Partial Volume Correction Methods for 18F-Flutemetamol SUVR with Subcortical White Matter Reference Region. Katarzyna Adamczuk, PhD1, Alessandra Dentamaro2, Nicolas Pannetier,PhD,1, David Scott, PhD1, Joyce Suhy, PhD1, Michael Egan, MD3 and Cyrille Sur, PhD3, (1) Bioclinica, USA, (2) BioClinica, United Kingdom, (3) Merck & Co., Inc., USA
    Session Details: Diagnosis and Prognosis: Neuroimaging: P3-419, July 24, 9:30 AM–4:15 PM in Hall-F1
    Summary: A discussion on appropriate partial volume correction methods for amyloid SUVR data with subcortical white matter used as reference region.
  • A Polygenic AD Risk Score Predicts Amyloid Accumulation Over a 6-year Interval in Cognitively Intact Older Adults. Silvy Gabel, MSc1,2; Jolien Schaeverbeke, PhD1,2; Katarzyna Adamczuk, PhD3; Koen Van Laere, MD, PhD4; Patrick Dupont, PhD2; Christine Van Broeckhoven, PhD, DSc5,6; Kristel Sleegers, PhD, MD5,6 and Rik Vandenberghe, PhD, MD1,2,7, Alzheimer Research Centre, KU Leuven, Leuven, Belgium, (2) Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium, (3) Bioclinica, Inc., Newark, CA, USA, (4) Nuclear Medicine Department, UZ Leuven, Leuven, Belgium, (5) Neurodegenerative Brain Diseases group, Center for Molecular Neurology, VIB, Antwerp, Belgium, (6) Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, (7) Neurology Department, University Hospital Leuven (UZ Leuven, Campus Gasthuisberg), Leuven, Belgium
    Session Details: Poster IC-P068, July 21, 12:30 –1:45 PM (Hall-F1) and Oral presentation IC-07-03, July 21, 4:50–5 PM (Room – 183). Also Oral presentation O3-10-03 July 24, 4:45 – 5 PM (Hall - W375 A).
    Summary: Explore findings of polygenic AD risk score in predicting amyloid accumulation in cognitively intact older adults.
  • Aptest Dementia Screening Test Compared to the Mini Mental State Exam for Detection of Mild Cognitive Impairment. Pamela Voccia, Katherine Kruczek, Jennifer Cody and Psychometric Rating & Prescreening Team, Bioclinica Research, The Villages, FL, USA
    Session Details: P2-11, Diagnosis and Prognosis: Neuropsychology, July 23, 9:30 AM– 4:30 PM in Hall F1 with discussion by Pamela Voccia from 9:30-10:30 AM.
    Summary: This poster session focuses on Aptest, a dementia prescreening test developed by Bioclinica's Pamela Voccia and used at Florida research sites. Since adopted at the Villages site in March 2017, the use of Aptest has reduced screen fail rate on scales by 70 percent.
  • Memory Concerns as a Motivating Factor for Voluntary Participation in Alzheimer's Dementia Research in a Homogeneous Mid-Socioeconomic Status Population. Pamela Voccia; Katherine Kruczek; Cristina Montes de Oca; Chelsea Montalvo, Bioclinica Research, The Villages, FL, US
    Session Details: P4-17, July 25, 9:30 AM ̶ 4:30 PM with discussion by Pamela Voccia from 9:30 -10:30 AM.
    Summary: This poster session explores motivational factors of subjects who voluntarily presented for consideration for Alzheimer's disease research, the majority of whom were not reporting memory concerns beyond age associated memory loss. Findings also show reliability of self-reports of memory from the population studied.

View the full AAIC program and get any last-minute updates!

Join the Conversation! #AAIC18

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Ck out best-of-breed trial #technologies & services: #RTSM, #esource, #EDC, site & patient #payments, global site… https://t.co/DJCNZ9C1uq
Bioclinica (2 days ago)
ICYMI: A discussion on recently released FDA draft guidance on assessment of blood pressure response in… https://t.co/7fmrkhhuQd
Bioclinica (2 days ago)
Our CIO & EVP Tech Gavin Nichols adds to #digitaltransformation discussion at #CMAsummit18 : W genomics & precision… https://t.co/oisqWvGJXC
Bioclinica (4 days ago)
Greetings from Tokyo where @bioclinica's Japan. China & US locations R@DrugInfoAssn DIA Japan. Discuss region-spec… https://t.co/HMzmFwA9pm
Bioclinica (6 days ago)
Reminder to join us in a live #Xtalks webinar tomorrow 11/6 on Electronic Data Capture (EDC). Everything clinical t… https://t.co/WS0L3QQnPv
Bioclinica (2 weeks ago)
Meet with representatives of Bioclinica's Japan, China & US locations at DIA Japan. Angel Y., Hidenori Seshimo & Er… https://t.co/j1alTH8oBm
Bioclinica (2 weeks ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner